Avalo Therapeutics Inc.
03/27/2026 | Press release | Distributed by Public on 03/27/2026 14:01
Management Change/Compensation (Form 8-K)
Item 5.02 Departure of Directors or Certain Officers; Election of Directors.
On March 23, 2026, Dr. Jonathan Goldman and Mitchell Chan, members of the board of directors (the "Board") of Avalo Therapeutics, Inc. (the "Company"), each notified the Company of his decision to not stand for re-election to the Board at the Company's 2026 Annual Meeting of Stockholders (the "2026 Annual Meeting"). Dr. Goldman and Mr. Chan will each continue to serve as a member of the Board until the 2026 Annual Meeting. Their decisions not to stand for re-election are not the result of any disagreement with the Company on any matter relating to its operations, policies or practices. The Board thanks Mr. Chan and Dr. Goldman for their service and contributions.
1
Avalo Therapeutics Inc. published this content on March 27, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on March 27, 2026 at 20:02 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]